Römer Thomas, Frenz Ann-Kathrin, Dietrich-Ott Susanne, Fiedler Anja
Obstetrics and Gynecology Department, Academic Hospital Weyertal, University of Cologne, Cologne, Germany.
Medical Affairs, Bayer AG, Berlin, Germany.
Arch Gynecol Obstet. 2024 May;309(5):2021-2030. doi: 10.1007/s00404-024-07421-5. Epub 2024 Feb 29.
The Kyleena™ Satisfaction Study (KYSS) provided the first data on 19.5 mg levonorgestrel-releasing intrauterine system (LNG-IUS-19.5 mg) use in routine clinical practice. Here we report results from the German participants in KYSS.
This prospective, observational, single-arm cohort study recruited women who independently chose to use LNG-IUS-19.5 mg during routine counseling in Germany. Overall satisfaction and bleeding profile satisfaction, continuation rates, and safety profile were evaluated at 12 months or premature end of observation (EoO).
In the German study population, LNG-IUS-19.5 mg placement was attempted in 508 women and successful in 506 women. Mean age was 32.3 years, and 60.0% (n = 305/508) were parous. Placement was considered easy and associated with no more than mild pain, even in younger and nulliparous participants. Of those with satisfaction data available, 87.6% (n = 388/443) were satisfied with LNG-IUS-19.5 mg at 12 months/EoO. Satisfaction was similar for parous (86.9%, n = 238/274) and nulliparous (88.8%, n = 150/169) women, and was independent of age, prior contraceptive method, or reason for choosing LNG-IUS-19.5 mg. Most participants (73.6%, n = 299/406) were also satisfied with their bleeding profile at 12 months/EoO, independent of parity, age, prior contraceptive method, presence of amenorrhea or dysmenorrhea severity. The 12-month continuation rate was 84.1% (n = 427/508). Most discontinuations were due to loss to follow-up (8.5%, n = 43/508) or treatment-emergent adverse events (TEAEs) (4.7%, n = 24/508). TEAEs were reported in 12.6% (n = 64) of participants, with 9.3% (n = 47) considered to have an LNG-IUS-19.5 mg-related TEAE.
Our real-world findings on LNG-IUS-19.5 mg use in German KYSS participants reflected its suitability for a broad population, including young and nulliparous women.
NCT03182140 (date of registration: June 2017).
Kyleena™满意度研究(KYSS)提供了关于19.5毫克左炔诺孕酮宫内节育系统(LNG-IUS-19.5毫克)在常规临床实践中使用的首批数据。在此,我们报告德国KYSS参与者的研究结果。
这项前瞻性、观察性、单臂队列研究招募了在德国常规咨询期间自主选择使用LNG-IUS-19.5毫克的女性。在12个月或观察提前结束(EoO)时评估总体满意度、出血情况满意度、持续使用率和安全性。
在德国研究人群中,508名女性尝试放置LNG-IUS-19.5毫克,506名女性放置成功。平均年龄为32.3岁,60.0%(n = 305/508)已生育。即使在年轻未生育的参与者中,放置也被认为容易且仅伴有轻度疼痛。在有满意度数据的参与者中,87.6%(n = 388/443)在12个月/EoO时对LNG-IUS-19.5毫克感到满意。已生育女性(86.9%,n = 238/274)和未生育女性(88.8%,n = 150/169)的满意度相似,且与年龄、既往避孕方法或选择LNG-IUS-19.5毫克的原因无关。大多数参与者(73.6%,n = 299/406)在12个月/EoO时也对其出血情况感到满意,与产次、年龄、既往避孕方法、闭经情况或痛经严重程度无关。12个月持续使用率为84.1%(n = 427/508)。大多数停用是由于失访(8.5%,n = 43/508)或治疗中出现的不良事件(TEAE)(4.7%,n = 24/508)。12.6%(n = 64)的参与者报告了TEAE,其中9.3%(n = 47)被认为有与LNG-IUS-19.5毫克相关的TEAE。
我们对德国KYSS参与者使用LNG-IUS-19.5毫克的真实世界研究结果表明,它适用于包括年轻未生育女性在内的广泛人群。
NCT03182140(注册日期:2017年6月)